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Abstract
Pilocarpine is commonly used after angle surgery for glaucomaBackground: 
despite a host of side effects and risks. We hypothesized that a 
pharmacological miosis during the first two months does not improve short- and
long-term results of trabectome-mediated   trabeculectomy.ab interno
 In this retrospective comparative 1-year case series, we comparedMethods:
187 trabectome surgery eyes with (P+) or without (P-) 1% pilocarpine for two
months. Primary outcome measures were the surgical success defined as
intraocular pressure (IOP) ≤ 21 mmHg and decreased ≥ 20%, and no
secondary glaucoma surgery. Secondary outcome measures were the number
of glaucoma medications, complications, and IOP.
We categorized 86 (46%) eyes as P- and 101 (54%) eyes as P+. TheResults: 
mean age was 69.8±10.1 in P- and 70.5±9.4 in P+ (P=0.617) with equal gender
distribution (P=0.38). The cumulative probability of qualified success at 12
months was 78.1% in the P- and 81% in the P+ (P=0.35). The IOP was
decreased significantly from 20.2±6.8 mmHg at baseline to 15.0±4.8 mmHg at
12 months follow-up in P- (P=0.001) and 18.8±5.3 and 14.7±4.0, respectively
(P=0.001). The medications decreased significantly from 1.4±1.2 in P- and
1.4±1.2 in P+ at baseline to 1.0±1.2 and 0.7±1.0, respectively (P=0.183). P- 
and P+ did not differ in IOP or medications (all P>0.05). In Multivariate Cox
Regression models, the baseline IOP and central corneal thickness were
associated with failure.
Use of postoperative pilocarpine does not improve the efficacyConclusions: 
of trabectome surgery.
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Introduction
Ab interno angle surgeries that disrupt or bypass the trabecular 
meshwork (TM) are bleb-less procedures without the need for 
office procedures and application of antifibrotics, the frequency 
of postoperative visits can be reduced1. Most surgeons admin-
ister pilocarpine hydrochloride 1% for two months to decrease 
the apposition between iris root and trabecular meshwork 
and minimize the risk of peripheral anterior synechiae (PAS) 
formation. Although this seems intuitive, miotics shallow 
the anterior chamber when the ciliary muscle contracts and 
can cause angle closure in phakic eyes2. There is no correla-
tion between the degree of PAS formation and the amount of 
intraocular pressure (IOP) elevation after trabectome surgery3,4, 
a common and mature form of ab interno trabeculectomy5 
appropriate for different types of glaucomas, including angle 
closure6, pigmentary7, exfoliative8, steroid-induced9, uveitic10, and 
advanced glaucomas11, as well as failed trabeculectomy and 
glaucoma shunt procedure12,13.
Pilocarpine is a nonselective muscarinic receptor agonist that 
has been used extensively in the medical management of glau-
coma for almost 150 years14. It attaches to muscarinic receptors 
on ciliary smooth muscle and causes contraction of the longitu-
dinal fibres. Following longitudinal muscle contraction, scleral 
spur is pulled back leading to expansion of juxtacanalicular por-
tion of the TM and Schlemn’s canal (SC) and consequently 
enhance the aqueous outflow15,16. However, a TM-mediated 
IOP effect, for instance by adding cataract surgery, becomes 
negligible after trabectome surgery17,18, because the aqueous can 
bypass the remaining TM. Patients dislike miotics because of 
their side effects of headaches, nearsightedness, dim vision and 
more serious problems that include retinal detachment, worsen-
ing intraocular inflammation, paradoxical increase in IOP and 
cataract formation19–23.
Since there is no evidence that pilocarpine decreases PAS for-
mation after trabectome surgery24, along with the fact that PAS 
is not a risk factor for trabectome failure established without 
doubt25, we hypothesized that postoperative pilocarpine does 
not improve the outcome and stopped its use in our practice. 
The present study compares the outcome of operation with 
pilocarpine versus no pilocarpine to test out hypothesis.
Methods
Institutional Review Board approval was obtained from the Uni-
versity of Pittsburgh Human Subjects Research Committee 
(approval number: PRO13120466). An informed consent from 
the patients was waived due to the low risk nature of this 
retrospective study. We followed the tenets of the Declaration of 
Helsinki and regulations of the Health Insurance Portability and 
Accountability Act.
Study design
This retrospective comparative study included all patients who 
underwent Trabectome surgery between July 2012 and October 
2017 at the Eye and Ear Institute of the University of Pittsburgh, 
School of Medicine, in Pittsburgh, PA, United States. Patients 
were identified using current procedural terminology codes of Eye 
and Ear Institute, University of Pittsburgh.
Participants
Patients were included regardless of same-session phacoemul-
sification, because the impact of same-session phacoemulsifica-
tion on IOP is negligible in trabectome surgery17,18. Eyes were 
categorized as P- if no pilocarpine was used after the surgery, 
and P+ if pilocarpine was administered postoperatively.
Exclusion criteria were a history of incisional and angle sur-
geries, combined glaucoma surgeries, use of pilocarpine in 
the contralateral eye, any systemic medication with parasympatho-
mimetic activities, and less than 3 months follow-up.
Information collected included demographic data, types of 
glaucoma, pre- and postoperative intraocular pressures (IOP), 
baseline ocular biometric characteristics including axial length 
(AL), central corneal thickness (CCT), anterior chamber depth 
(ACD), number of pre-and postoperative glaucoma medica-
tions, visual field mean deviation (MD), visual field index (VFI), 
type of surgery, use of pilocarpine eye drop after the surgery, and 
intra- and postoperative complications.
The primary outcome measure was success and defined as 5 < 
IOP ≤ 21 mmHg, ≥ 20% reduction of IOP from baseline at two 
consecutive visits, no need for further glaucoma surgery, and 
no loss of light perception. Qualified success was defined as 
achieving success with or without medications. Patients who 
achieved success without medication were labeled as complete 
success. A Kaplan Meier survival analysis was used to evaluate 
success rates. The secondary outcome measures were IOP, 
glaucoma medications, and complications.
Surgical technique
In the case of combined phacoemulsification, trabectome 
(NeoMedix, Tustin, CA, USA) portion was performed first. Both 
the patient’s head and microscope were tilted 30° away from 
the surgeon. A temporal 1.6 mm incision was made 2 mm ante-
rior to the limbus and parallel to the iris plane. The trabectome 
was inserted through the incision and positioned across the AC 
along the nasal angle. The tip of the trabectome was inserted 
into Schlemm’s canal and engaged with the TM. The aspira-
tion and ablation was activated with the power set to 0.8 to 1W 
and the TM removed over approximately 160°. The tip was with-
drawn from anterior chamber and the incision was hydrated to 
achieve watertightness. All glaucoma medications were discon-
tinued after the surgery and were resumed if IOP was not within 
target range. In P+, 1% pilocarpine was used 4 times a day 
for one month followed by three times a day for a second month.
Statistical analysis
All analyses were performed using SPSS software (SPSS Statis-
tics for Windows, Version 25, Armonk, NY, IBM Corporation). 
Frequency, percent, mean±SD, median, and range were used to 
describe the data. To evaluate the baseline differences between the 
two study groups, we used the T-test, Mann Whitney, and 
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Chi-Square test. To compare the change in IOP and number 
of medications between the two groups or within a group, we used 
an interaction analysis within a linear mixed model. To compare 
the amount of IOP reduction between the groups adjusted for the 
baseline values, we used an Analysis of Covariance (ANCOVA). 
Kaplan-Meier survival plots were constructed to assess the 
long-term survival rates and compared by the log-rank test. 
A Cox proportional Hazard model was used to find risk factors 
for failure and to estimate the adjusted Hazard ratio of each fac-
tor. In the last step to obtain the most important factors, we used 
a backward variable elimination method based on the LR test. 
Statistical significance was set at p< 0.05. Success was defined 
as IOP <21 mmHg and a >20% reduction from baseline with 
no need for additional glaucoma surgery.
Results
Baseline characteristics
A total of 187 eyes were included in this study. Eighty-six 
(46%) eyes in P- did not receive pilocarpine, while 101 (54%) 
in P+ did (Table 1). All patients were phakic at the time of sur-
gery. Phacoemulsification was combined in 147 (79%) eyes (TP) 
while 40 eyes had trabectome surgery alone (T). The mean age 
of participants was 69.8±10.1 in P- and 70.5±9.4 in P+. Primary 
open-angle glaucoma was the most common diagnosis in both 
groups (73.3% and 63.2% in P- and P+, respectively, P=0.64). 
There were no significant differences between the study groups in 
terms of gender, preoperative intraocular pressure, central corneal 
thickness, axial length, visual field mean deviation, anterior 
chamber depth, baseline number of glaucoma medications, and 
type of glaucoma (Table 1).
Surgical success and risk factors for failure
Kaplan-Meier survival curves (Figure 1) indicated a mean sur-
vival of 34.03±2.35 months in P- and 38.32±1.94 months in P+ 
with no statistically significant difference between two groups 
(log rank:0.87 P=0.35). The addition of phacoemulsifica-
tion did not make a difference on survival (T: 33.9±3.2 months; 
TP: 32.3±1.7, log-rank:0.81 P=0.36). Similarly, pilocarpine did 
not have a significant effect on survival in T or TP: T in P- had 
a survival of 32.5±5.4 and T in P+ had a survival of 33.3±3.9 
months (log-rank:0.06, P=0.8). TP in P- had a survival of 33.6±2.4 
and TP in P+ had a survival of 36.2±2.2 months (log-rank:0.81, 
Table 1. Baseline clinical characteristics of patients in P- and P+.
All P- P+ p-value
Age 70.1±9.7 69.8±10.1 70.5±9.4 0.617†
Gender Female 99 (52.9%) 44 (52.1%) 55 (54.5%) 0.380*
Male 88 (47.1%) 42 (48.8%) 46 (45.5%)
Glaucoma type POAG 68.4% 73.3% 63.2% 0.640*
CACG 11.1% 8.3% 14.0%
XFG 10.3% 10.0% 10.5%
Others 10.3% 8.3% 12.3%
Axial length (mm) 24±2.2 24±2.9 24.1±1.2 0.915†
CCT 544±40 549±44 540±37 0.154†
AC depth (mm) 3.1±0.6 3.05±0.6 3.2±0.6 0.061†
Lens thickness (mm) 4.4±0.8 4.5±0.6 4.3±1.0 0.129†
HVF MD -6.6±7.9 -7.6±8.7 -5.9±7.2 0.079‡
IOP (mmHg) 19.5±6.1 20.2±6.8 18.8±5.3 0.120†
Medications 1.4±1.2 1.4±1.2 1.4±1.2 0.902‡
†Based on T-test. *Based on Chi-square. ‡ Based on Mann-Whitney test.  
AC: Anterior chamber, CACG: Chronic angle closure glaucoma,  
CCT: Central corneal thickness, HVF MD: Humphrey Visual Field Mean Deviation,  
IOP: intraocular pressure, POAG: primary open angle glaucoma, XFG: exfoliation glaucoma.
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Figure 1. Kaplan-Meier survival plots for P- and P+ with success defined as a final intraocular pressure of ≤ 21 mmHg and a 20% 
reduction from baseline. Success rates were similar in both groups. Survival plots of P- and P+ for subgroup analysis separated by 
B) glaucoma surgery alone and C) same session phacoemulsification.
P=0.36). The multivariate Cox regression model was stratified 
by group, age, baseline IOP, number of medications, glaucoma 
type, CCT, AC depth, lens thickness, axial length, Humphrey 
visual field (HVF) MD and VFI (Table 2). The final model with 
backward elimination only included baseline IOP (mmHg) and 
CCT (micron) with HR of 4.1 for 22<IOP<28, 3.7 for IOP>28, 
and 1.03 for CCT. This means that in patients with 22<IOP<28 
the risk of failure was 4.1 times higher compared to patients 
with IOP<18 (P=0.015). Every 10 micron increase in baseline 
CCT increased the risk of failure by 30% (P=0.005).
IOP change
IOP was decreased significantly from 20.2±6.8 mmHg at base-
line to 15.0±4.8 mmHg at 12 months follow-up in P- (P=0.001, 
Figure 2). The corresponding numbers for P+ were 18.8±5.3 
and 14.7±4.1, respectively (P=0.001). There was no significant 
difference in IOP at each follow-up visit between the two 
groups (Table 3). In subgroup analysis, considering the effect 
of phacoemulsification, there was no significant difference 
between IOPs of both groups in T and TP throughout the course 
of follow-up (Figure 2). Seven (8.1%) cases in P- and five (5%) 
in P+ experienced IOP spikes. There was no significant differ-
ence between the groups (P=0.153, based on the Chi-square test). 
The baseline number of glaucoma medications was 1.4±1.2 
in P- and 1.4±1.2 in P+ (P=0.910). At month 12, the number of 
glaucoma medications was 1.0±1.2 drops in P- and 0.7±1.0 in 
P+ (P=0.082, Table 4).
The postoperative hyphema was observed in 49% of the eyes. 
The mean duration of hyphema was 10.68±9.96 days in P- and 
12±4.30 days in P+ (P= 0.48).
Table 2. Hazard ratios of risk factors 
for failures. Results from multivariate cox 
proportional hazard regression model. 
IOP, intraocular pressure; T, trabectome 
surgery; TP, trabectome surgery with 
phacoemulsification; CCT, central corneal 
thickness; AC, anterior chamber depth; HVF 
MD, Humphrey Visual Field Mean Deviation; 
HVF VFI, Humphrey Visual Field visual field 
index.
Risk factor HR (95% CI) p-value
Pilocarpine use 0.62 (0.14-2.63) 0.52
Age 0.99 (0.91-1.09) 0.45
Gender 0.57 (0.16-2.0) 0.38
Glaucoma type 0.94 (0.09-12.3) 0.97
18<IOP<22 1.36 (0.33-5.5) 0.66
22<IOP<28 4.1 (1.31-12.84) 0.015
IOP>28 3.74 (1.13-12.35) 0.03
Baseline 
medications 2.11 (0.92-4.83) 0.07
T vs TP 1.61 (0.37-6.9) 0.52
CCT 1.03 (1.01-1.04) 0.005
AC depth 0.84 (0.23-3.03) 0.79
Axial length 1.18 (0.66-2.14) 0.56
Lens thickness 0.5 (0.18-1.37) 0.18
HVF MD 1.0 (0.99-1.02) 0.46
HVF VFI 1.008 (0.98-1.02) 0.44
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Figure 2. Intraocular pressure (IOP) in P- and P+ groups. A) IOP in P- was similar to P+ through follow-up duration. IOP in both groups for 
subgroup analysis separated by B) glaucoma surgery alone. Patients who received pilocarpine showed lower IOPs during the first month but 
the difference was not statistically significant. C) Same session phacoemulsification. Error bars represent standard deviations.
Table 3. Mean intraocular pressure (IOP) 
and IOP change over time.
P- P+ p-value
Baseline 20.2±6.8 18.8±5.3 0.12
Day 1 15.1±9.0 15.0±7.0 0.482
Week 1 13.7±6.7 13.0±4.0 0.427
Month 1 14.9±5.4 14.0±5.1 0.814
Months 3 13.9±3.7 13.6±3.7 0.417
Month 6 14.3±4.0 13.9±3.6 0.301
Month 12 15.0±4.8 14.7±4.0 0.274
Table 4. Mean number of glaucoma 
medications.
P- P+ p-value
Baseline 1.4±1.2 1.4±1.2 0.91
Month 1 0.5±1.0 0.3±0.7 0.413
Months 3 0.4±1.0 0.3±0.7 0.523
Month 6 0.5±1.0 0.4±0.8 0.569
Month 12 1.0±1.2 0.7±1.0 0.183
Dataset 1. Raw data collected from all study participants. Coding 
scheme for the data contained in Word document
http://dx.doi.org/10.5256/f1000research.13756.d193749
Discussion
Miotics are commonly used at the conclusion of cataract surgery 
to retract a floppy iris from the incision26 or to secure a sulcus 
lens implant after a complex cataract surgery27. It is, therefore, 
not surprising that ab interno glaucoma surgeons resort to the 
same medications despite reports of worsening of iritis28,29, 
retinal detachment and further angle narrowing, as the most 
serious complications19–23. Interestingly, a narrow angle is not a 
contraindication to trabectome surgery and yields similar results 
to wide angles6. In the current study, the survival, IOP reduc-
tion, and duration of postoperative hyphema were comparable 
regardless of pilocarpine use. Both groups experienced an IOP 
reduction like that observed in previous studies5,6,30.
It is unclear what may cause a late failure after trabectome sur-
gery as the aqueous humor is not redirected into a conjunc-
tival bleb maintained by antifibrotics or into tube shunts and 
microbypasses that cause a chronic foreign body reaction. Cer-
tainly, descemetization31 of the outer wall of Schlemm’s canal 
and PAS formation may be causes of surgical failure4,5,32, but 
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it is not established whether miotics prevent this. Additionally, 
the incidence of PAS ranges from 20% to 40% which does not 
match the relatively high success rate observed with this pro-
cedure3–5. In one study by Minckler et al., the incidence of PAS 
was 38%33, while in another study by Wang et al. without 
pilocarpine, the incidence of PAS was 20%4. 
The results of our study match established findings from other 
studies that higher baseline IOP is associated with larger IOP 
reduction5,25. It is consistent with the fact that after removing the 
site of the highest outflow resistance by trabectome, aqueous 
outflow would be limited only by downstream pathway. While 
post-trabectome IOPs tend to be similar in all patients, those 
with higher preoperative IOP experience larger IOP reduction11. 
Our study indicates a link between corneal biomechanics and 
risk of failure following trabectome surgery. Corneal thickness 
serves as an in vivo surrogate marker of corneal rigidity and is 
associated with biomechanical properties of the cornea34 and 
likely the sclera35–37. After trabecular ablation, outflow is only 
limited by the remaining outflow resistance in collector chan-
nels and episcleral veins. The collector channels and the 
intrascleral plexus have features that indicate they can regu-
late the outflow resistance like the remainder of the vascu-
lar system38,39. This novel finding invites further researches to 
clarify the role of corneal and scleral biomechanics in predicting 
the behavior of the downstream pathway in angle surgery.
This study was limited by its retrospective nature and number 
of patients. It was powered to detect a difference of 2 mmHg 
between the two groups (power 0.8, alpha 0.5), a clinically 
meaningful difference. It would have required close to 360 
individuals in each group to detect a 1 mmHg difference. Patients 
were not randomized or matched and PAS was not assessed 
systematically.
In conclusion, our study indicates that administering pilo-
carpine eye drop after trabectome surgery does not improve the 
outcome of the procedure. Given the multitude of side effects, 
we recommend it be avoided. A thicker cornea was associated 
with a higher risk of failure.
Data availability
Dataset 1: Raw data collected from all study participants. 
Coding scheme for the data contained in Word document. DOI, 
10.5256/f1000research.13756.d19374940
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